Jilin Aodong Pharmaceutical Group Co., Ltd.

SZSE:000623 Stock Report

Market Cap: CN¥15.6b

Jilin Aodong Pharmaceutical Group Past Earnings Performance

Past criteria checks 2/6

Jilin Aodong Pharmaceutical Group has been growing earnings at an average annual rate of 6.1%, while the Pharmaceuticals industry saw earnings growing at 9.2% annually. Revenues have been growing at an average rate of 1.4% per year. Jilin Aodong Pharmaceutical Group's return on equity is 3.8%, and it has net margins of 31.7%.

Key information

6.1%

Earnings growth rate

6.9%

EPS growth rate

Pharmaceuticals Industry Growth10.9%
Revenue growth rate1.4%
Return on equity3.8%
Net Margin31.7%
Next Earnings Update31 Aug 2024

Recent past performance updates

There Might Be More To Jilin Aodong Pharmaceutical Group's (SZSE:000623) Story Than Just Weak Earnings

Apr 23
There Might Be More To Jilin Aodong Pharmaceutical Group's (SZSE:000623) Story Than Just Weak Earnings

Recent updates

Jilin Aodong Pharmaceutical Group (SZSE:000623) Is Increasing Its Dividend To CN¥0.60

Jul 05
Jilin Aodong Pharmaceutical Group (SZSE:000623) Is Increasing Its Dividend To CN¥0.60

Investors Holding Back On Jilin Aodong Pharmaceutical Group Co., Ltd. (SZSE:000623)

Jun 03
Investors Holding Back On Jilin Aodong Pharmaceutical Group Co., Ltd. (SZSE:000623)

There Might Be More To Jilin Aodong Pharmaceutical Group's (SZSE:000623) Story Than Just Weak Earnings

Apr 23
There Might Be More To Jilin Aodong Pharmaceutical Group's (SZSE:000623) Story Than Just Weak Earnings

Revenue & Expenses Breakdown

How Jilin Aodong Pharmaceutical Group makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

SZSE:000623 Revenue, expenses and earnings (CNY Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
31 Mar 243,5231,1181,368131
31 Dec 233,4491,4601,375125
30 Sep 233,3092,1751,36999
30 Jun 233,2012,3491,32699
31 Mar 233,0192,2071,19988
01 Jan 232,8681,7811,19386
30 Sep 222,6189681,10662
30 Jun 222,4711,3131,06748
31 Mar 222,4171,4481,09449
01 Jan 222,3041,7811,09849
30 Sep 212,2341,8981,15151
30 Jun 212,2131,6511,18264
31 Mar 212,3071,7721,29469
31 Dec 202,2521,7091,27867
30 Sep 202,3461,7481,33783
30 Jun 202,5671,5521,468100
31 Mar 202,7341,0871,486106
31 Dec 193,0881,4041,745143
30 Sep 193,2861,1991,895138
30 Jun 193,3861,1991,969111
31 Mar 193,4391,2552,046127
31 Dec 183,3249351,94888
30 Sep 183,3861,3901,897133
30 Jun 183,3321,5601,844140
31 Mar 183,1831,7701,77199
31 Dec 172,9771,8631,63092
30 Sep 172,8691,7541,59720
30 Jun 172,7451,7391,5440
31 Mar 172,6701,7211,4910
31 Dec 162,7371,6661,5070
30 Sep 162,5431,8571,3710
30 Jun 162,4131,7721,3260
31 Mar 162,3782,3701,2840
31 Dec 152,3352,5941,2580
30 Sep 152,2412,5151,1910
30 Jun 152,2442,5301,1530
31 Mar 152,2411,7671,1590
31 Dec 142,2401,4111,1690
30 Sep 142,2711,2741,2260
30 Jun 142,2271,1751,2230
31 Mar 142,0911,0971,1560
31 Dec 131,9571,0591,0900
30 Sep 131,7528009290

Quality Earnings: 000623 has high quality earnings.

Growing Profit Margin: 000623's current net profit margins (31.7%) are lower than last year (73.1%).


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: 000623's earnings have grown by 6.1% per year over the past 5 years.

Accelerating Growth: 000623's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.

Earnings vs Industry: 000623 had negative earnings growth (-49.4%) over the past year, making it difficult to compare to the Pharmaceuticals industry average (-0.8%).


Return on Equity

High ROE: 000623's Return on Equity (3.8%) is considered low.


Return on Assets


Return on Capital Employed


Discover strong past performing companies

Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.